1198408-39-7

Basic information

• Product Name: LDN-211904
• Synonyms: LDN-211904;N-(2-chlorophenyl)-6-(piperidin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide;N-(2-Chlorophenyl)-6-(4-piperidinyl)-imidazo[1,2-a]pyridine-3-carboxamide
• CAS NO: 1198408-39-7
• Molecular Formula: C₁₉H₁₉ClN₄O
• Molecular Weight: 354.83336
• EINECS: -0
• Mol File: 1198408-39-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: LDN-211904(CAS DataBase Reference)
• NIST Chemistry Reference: LDN-211904(1198408-39-7)
• EPA Substance Registry System: LDN-211904(1198408-39-7)

Safety Data

• Hazardous Substances Data: 1198408-39-7(Hazardous Substances Data)

Usage

General Description

LDN-211904, also known as BMS-986115, is a small molecule drug that has shown potential as a treatment for inflammatory and autoimmune diseases. It works by inhibiting the activity of a protein called Janus kinase 1 (JAK1), which plays a key role in triggering inflammation in the body. By blocking the action of JAK1, LDN-211904 can help reduce the production of inflammatory signaling molecules, thereby dampening the immune response and alleviating symptoms associated with conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Clinical trials of LDN-211904 have demonstrated promising results in terms of both safety and efficacy, and researchers are continuing to investigate its potential as a therapeutic agent for various inflammatory disorders.

Upstream product

• 1198408-37-5 C₂₄H₂₇ClN₄O₃ 

Downstream Products

• 1198408-78-4 LDN-211904 

Relevant articles and documents

Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors

A structure-activity relationship study for a 2-chloroanilide derivative of pyrazolo[1,5-a]pyridine revealed that increased EphB3 kinase inhibitory activity could be accomplished by retaining the 2-chloroanilide and introducing a phenyl or small electron donating substituents to the 5-position of the pyrazolo[1,5-a]pyridine. In addition, replacement of the pyrazolo[1,5-a]pyridine with imidazo[1,2-a]pyridine was well tolerated and resulted in enhanced mouse liver microsome stability. The structure-activity relationship for EphB3 inhibition of both heterocyclic series was similar. Kinase inhibitory activity was also demonstrated for representative analogs in cell culture. An analog (32, LDN-211904) was also profiled for inhibitory activity against a panel of 288 kinases and found to be quite selective for tyrosine kinases. Overall, these studies provide useful molecular probes for examining the in vitro, cellular and potentially in vivo kinase-dependent function of EphB3 receptor.